neonadmin, Author at Solving Kids' Cancer

Will an Antibody Recognizing a New Target in Neuroblastoma Kill Tumor Cells?

In the lab, an antibody targeting ALK expression kills neuroblastoma cells. Researchers believe that an anti-ALK antibody that targets the surface antigen will alert the immune system to attack the cancer, reducing the risk of a future recurrence. This research is to develop, test, and produce clinical grade anti-ALK antibody. Project Title: Preclinical Development of…

Can Chemotherapy Be Delivered to the Brainstem in Children?

Solving Kids’ Cancer supported this new trial, which delivers chemotherapy directly into the vertebrobasilar system, because it represents a novel way to treat the disease by targeting the blood supply to these tumors. This delivery method allows doctors to increase the dose of the drug to kill the cancer, while minimizing toxicity in other parts…

Can a Vaccine Made From a Child’s Immune Cells Work Against Deadly Brain Tumors?

This new treatment targets glioma-associated antigens, which are overexpressed in ependymomas, making them ideal candidates for the immunotherapy researchers previously developed. This cutting-edge research represents the first immunotherapy trial ever for kids with ependymomas. Project Title: Pilot Study Peptide-based vaccination for recurrent ependymomas Researcher: Ian F. Pollack, MD Institution: Children’s Hospital of Pittsburgh Study Type:…

Can Engineered T-Cells Be Improved to Better Recognize and Attack Neuroblastoma Cells?

T-cell therapy has seen much success in leukemia patients. Researchers now are trying to find out if T-cell therapy using the GD2 tumor antigen, which is on the surface of the neuroblastoma cancer cells, can bring about remission in solid tumors. Project Title: Adoptive Cell Therapy for Adolescent/pediatric Solid Tumors: Part II Researcher: Stephen Grupp,…

Will Combining NK Cells From a Parent With a Humanized Antibody Be More Effective in Treating Neuroblastoma and Osteosarcoma?

Solving Kids’ Cancer supported this trial because researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for killing the cancer cells. Project Title: hu14.18/IL-2 + KIR ligand mismatch natural killer cells Researcher:…

Can T-Cells Be Engineered to Attack More Types of Pediatric Solid Tumors?

Researchers optimized the activity of a CAR (chimeric antigen receptor) constructed that targets GD2, an antigen on the surface of neuroblastoma to modify T cells for use in a future clinical trial. Project Title: Adoptive Cell Therapy for Adolescent/Pediatric Solid Tumors: Part I Researcher: Rimas Orentas, PhD Institution: National Cancer Institute Pediatric Oncology Branch Study…

Can We Improve the Potency and Persistence of a Child’s T-Cells to Recognize and Kill Neuroblastoma Cells?

Solving Kids’ Cancer supported this work to develop a new and improved type of GD2-CAR T cells, and this work has advanced to a Phase I clinical trial also supported by Solving Kids’ Cancer. Project Title: Improving GD2 T-cell Immunotherapy for Patients with Neuroblastoma Researcher: Chrystal Louis, MD Institution: Baylor College of Medicine Study Type:…

Will a Vaccine Made of Stem Cells Be Effective Against a Deadly Brain Tumor in Children?

Solving Kids’ Cancer identified a novel trial using a cancer vaccine modeled after one used in adults for a deadly brain tumor called glioblastoma. As part of this trial, the vaccine will be combined with the drug imiquimod, which enhances the response of the immune system to attack and kill cancer cells. Project Title: Pilot…

Can We Train a Child’s Immune Cells to Recognize and Kill Cancer Cells?

Solving Kids’ Cancer supported this vaccine clinical trial that uses the cancer drug decitabine to help the immune cells better recognize and kill the cancer cells. Project Title: Combining Decitabine and Vaccine Therapy for Patients with Relapsed Neuroblastoma and Sarcoma Researcher: Kenneth Lucas, MD Institutions: University of Louisville Study Type: Phase I clinical trial Status:…

Will Targeted Radiation Stop a Deadly Brain Tumor?

Solving Kids’ Cancer supported this project because better methods to deliver treatments to the brain stem are urgently needed. In this research study, children with DIPG are treated with an antibody connected to a radioactive isotope and delivered directly to the tumor in the brain stem through a novel technique. Project Title: Image-guided Convection-enhanced Delivery…